Schrödinger (SDGR): Buy a Software-Led AI Play Before the Re-rating

Hook & thesis

Schrf6dinger (SDGR) is one of the rarer public stocks that sits squarely at the intersection of enterprise software economics and AI-accelerated drug discovery. The company already sells commercial chemical simulation tools to pharma and materials customers (recurring, high-margin software), while separately advancing drug discovery programs. The market is still pricing the company like a pre-profit biology play instead of a hybrid software vendor that can meaningfully re-rate if commercial momentum and AI adoption continue.

My trade thesis is simple: buy a position now to capture two things — near-term upside from improving software revenue visibility and an outsized multiple expansion should AI-driven demand for biosimulation accelerate. Key fundamentals (market cap ~$1.14B, enterprise value ~$871M, EV/Sales ~3.42x) and a reasonably healthy balance sheet create an asymmetric reward profile for patient capital over a long-term window.

What Schrf6dinger does and why it matters

Schrf6dinger operates two core businesses: a software segment selling chemical simulation and molecular modeling tools and a drug discovery segment advancing internal and collaborative programs. The software side is why the market should care: it sells tools that reduce trial-and-error in early discovery, speeding programs and lowering costs for pharma and materials customers. That is a classic software value proposition in a high priced, recurring-need vertical.

Recent industry research underscores the opportunity. The generative AI drug discovery market is expanding rapidly, growing from $0.25B in 2025 to $0.33B in 2026 with projections to reach $0.86B by 2030 at a ~27% CAGR (reported 07/10/2026). Separately, biosimulation markets are forecast to expand strongly through the next decade. Those sector tails make Schrf6dinger's software IP strategically valuable: customers chasing model-driven early discovery will likely turn to mature simulation tools as integration and validation work progresses.

Hard numbers that matter

• Market cap: roughly $1.14B.
• Enterprise value: ~$871M, yielding EV/Sales of ~3.42x using recent revenue context.
• Revenue context: analysts and sector write-ups cite software revenue around $256M for 2025, giving a tangible base for EV/Sales math.
• Profitability: GAAP EPS is negative at roughly -$1.38; free cash flow was negative about -$148.35M (recent period), showing the company is still investing heavily in growth and discovery programs.
• Balance sheet/liquidity: current and quick ratios are both ~2.69, and reported cash per share is about $1.54, providing cushion for continued R&D and commercial expansion.
• Valuation multiples: price-to-sales is ~4.44 and price-to-book ~3.6; the company trades well below SaaS growth comps where EV/Sales for high-growth software can be ~6-12x, implying upside if growth persists and margins improve.
• Share structure and short activity: float ~63.2M shares, short interest has been elevated with ~10.58M shares short as of 07/15/2026 and days-to-cover near 9.8; short volume on 08/03/2026 was ~60% of total volume (179k short of 297k total), which can amplify moves during positive news or buy flows.
• Near-term technicals: current price $15.29; 10-day SMA $15.17; 20-day SMA $15.61; 50-day SMA $15.32; RSI ~48 and MACD showing slightly bearish momentum. Price sits nearer the recent trading range low than the late-2025 high of $23.02.

Valuation framing

On an EV/Sales basis the company sits around 3.4x using enterprise value ~$871M and recent revenue context (~$256M in 2025). For a software company with recurring revenue and secular tailwinds from AI in drug discovery, that EV/Sales is not demanding — particularly given the potential for margin expansion as software mix rises versus drug discovery cash burn. Yes, Schrf6dinger still reports negative EPS and material negative free cash flow, but part of that is continued R&D investment in the drug pipeline which is optional leverage: the market can re-rate the stock if commercial software growth accelerates even without clinical upside.

Put differently: the market is effectively applying a biotech-style haircut to a company with meaningful subscription-like software revenue. If the market begins to compare SDGR to software peers rather than pure-play biotech, multiples could re-rate materially higher.

Catalysts (what could move the stock)

• Commercial: stronger-than-expected subscription renewals or new enterprise software contracts announced in the next 6-12 months that increase recurring revenue visibility.
• AI momentum: partnership announcements integrating generative AI or validated model workflows that accelerate adoption across pharma customers (press pieces on sector growth on 07/10/2026 and 04/27/2026 highlight this theme).
• Operational: measurable margin improvement or guidance that points to software mix expansion and narrower negative free cash flow trajectory.
• Macro/re-rating: a broader re-rating of AI/biosimulation names as institutional flows re-enter the sector.
• Short squeeze potential: elevated short interest and short-volume intensity can amplify moves on positive headlines or earnings beats.

Trade plan (actionable)

Recommendation: Enter a long position at $15.29. This is a position trade intended to capture a multiple re-rating and commercial acceleration over a long-term window.

• Entry price: $15.29
• Stop loss: $13.50 (a break below the recent trading range and psychological support; cut size to limit downside)
• Target: $21.00 (approaches prior area of interest toward the 52-week high and reflects a ~38% move that would be consistent with a re-rating to a higher EV/Sales multiple as software mix improves)
• Horizon: long term (180 trading days). I expect the thesis to play out over multiple quarters as enterprise sales cycles and AI integration timelines for pharma customers are not instantaneous. Give the commercial book time to build and for narrative catalysts to surface.

Position sizing: treat this as a tactical position within a diversified portfolio given the company's ongoing losses and development risk. Consider initial sizing ~2-4% of portfolio and scale up if revenue and margin inflection points appear.

Risks and counterarguments

Every trade has downsides. Below are the main risk factors and at least one counterargument to the bullish case.

• Clinical/program risk: the drug discovery segment is costly and can pull capital and focus away from the software business. Continued negative free cash flow (recently -$148.35M) could force either dilution or slower software investment.
• Profitability is not guaranteed: EPS is negative at about -$1.38. If software growth disappoints, the market could maintain a biotech-style valuation and the stock could trade lower.
• Execution risk on commercial adoption: enterprise sales cycles in pharma are long. If adoption of AI-driven biosimulation stalls or competitors win share, revenue growth could slow and keep multiples depressed.
• High short interest and volatility: elevated short interest (over 10M shares short recently) suggests potential for volatility — both upside squeezes and downside pressure on weak results.
• Macro and multiple compression: if risk appetite for growth/software names contracts again, SDGR could see its multiple compress further even with steady revenue growth.

Counterargument: A conservative investor could reasonably argue that Schrf6dinger will remain a bifurcated story where the market continues to discount software growth against drug discovery burn, preventing a meaningful re-rating. If the market prioritizes near-term profitability above all, software progress might not be enough to re-rate the stock quickly.

What would change my mind?

• I would upgrade conviction if the company reports sequential increases in recurring software bookings, clearer multi-year ARR targets, or margin guidance pointing to durable operating leverage.
• I would step back if software net retention shows signs of deterioration, if guidance is cut on subscription revenue, or if cash runway becomes constrained without a credible plan to reduce burn without sacrificing product investment.
• Significant dilution (large secondary offering) would also change the calculus — that would likely force a re-evaluation of valuation and potentially reduce the attractiveness of this trade.

Conclusion and stance

Schrf6dinger sits at a favorable crossroads: an established simulation software business with recurring revenue and a nascent but strategically aligned AI tail in drug discovery. At roughly $15.29 today, with EV/Sales near 3.4x and a ~$1.14B market cap, the stock offers a reasonable asymmetric bet where modest commercial wins or clearer software momentum could trigger a re-rating. The trade outlined above (entry $15.29, stop $13.50, target $21.00, horizon 180 trading days) balances that asymmetric upside with downside protection and acknowledges both execution and clinical risks.

If you believe AI and model-driven workflows will become central to early drug discovery and that the market will eventually prize software economics over biotech-style binary outcomes, SDGR is a compelling way to express that view. If you think the market will keep valuing hybrid stories through a biotech lens indefinitely, this trade is higher risk and worth smaller sizing.